Abstracts tagged "Rheumatoid Factor"

Abstract Number: 0015 • ACR Convergence 2021
Rheumatoid Factor Recognizes Specific Domains of IgG Heavy Chain Complexed with HLA Class II Molecules
Shanshan Zhang¹, Hideaki Tsuji¹, Hui Jin², Koji Kitagori¹, Shuji Akizuki³, Kosaku Murakami¹, Ran Nakashima¹, Hajime Yoshifuji¹, Masao Tanaka¹, Hisashi Arase², Koichiro Ohmura⁴ and Akio Morinobu¹, ¹Kyoto University, Kyoto, Japan, ²Osaka University, Osaka, Japan, ³Kyoto Universtiy, Kyoto City, Japan, ⁴Kobe City Medical Center General Hospital, Kobe, Japan
Background/Purpose: Rheumatoid factor (RF) is an autoantibody that binds to IgG Fc region (CH2 and CH3 domains) and is detectable in patients with rheumatoid arthritis…
Abstract Number: 0039 • ACR Convergence 2021
Elevated IgA Subclass Levels in Rheumatoid Arthritis Patients: Indications of a Mucosal Origin?
Veerle Derksen, Cornelia F. Allaart, Annette H.M van der Helm-van Mil, Tom WJ Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Mucosal surfaces may be involved in the pathophysiology of rheumatoid arthritis (RA) (1). IgA is the most abundant class of immunoglobulin at mucosal sites…
Abstract Number: 0253 • ACR Convergence 2021
Rheumatoid Factor Status as a Predictor of Disease Activity and Disability:An Analysis of the New CARRA Registry Polyarticular Juvenile Idiopathic Arthritis Cohort
Nayimisha Balmuri¹, William Soulsby², Victoria Cooley³, Linda Gerber⁴, Erica Lawson² and Karen Onel¹, ¹Hospital for Special Surgery, New York, NY, ²University of California San Francisco, San Francisco, CA, ³Weil Cornell Medicine, New York, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: Children with rheumatoid factor (RF) positive polyarticular JIA (pJIA) are less likely to go into remission and more likely to develop erosive disease than…
Abstract Number: 0269 • ACR Convergence 2021
Autoantibodies and the Risk of Incident Cardiovascular Disease in US Veterans with Rheumatoid Arthritis
Tate Johnson¹, Michael Duryee², Carlos Hunter², Punyasha Roul², Yangyuna Yang², Jeremy Sokolove³, William Robinson⁴, Joshua Baker⁵, Geoffrey Thiele², Ted Mikuls² and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Stanford University School of Medicine, Berwyn, PA, ⁴Stanford University, Stanford, CA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Autoantibodies are hypothesized as one of the RA specific factors contributing to a heightened risk of cardiovascular disease (CVD) in this population. However, prior…
Abstract Number: 0273 • ACR Convergence 2021
Abnormalities in Left Ventricular Geometry Influenced by Higher Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Titers in Rheumatoid Arthritis Patients
Natalia Guajardo-Jauregui, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Alejandra Rodriguez-Romero, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Catalina Andrade-Vazquez and Alan De Leon-Yañez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher risk of developing left ventricular (LV) geometry abnormalities which can result in cardiac death. High titers of…
Abstract Number: 0440 • ACR Convergence 2021
Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events
Kristen Mathias¹, Marco Lopez Velazquez¹ and Pankti Reid², ¹University of Chicago, Chicago, IL, ²University of Chicago Medical Center, Chicago, IL
Background/Purpose: The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy; however, their use can lead to off-target toxicities called immune-related adverse events (irAEs)…
Abstract Number: 0463 • ACR Convergence 2021
Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs
Sang Hee Park¹, Taylor Schwartz², Xue Han¹, Scott Robinson², Sumie Kakehi¹, Keith Wittstock¹, Kris Norris², Anne Murunga², Alison Silverstein² and Jeffrey Sparks³, ¹Bristol Myers Squibb, Princeton, NJ, ²Avalere Health, Washington, DC, ³Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Recent exploratory clinical trial and retrospective studies1 suggest that patients with seropositive RA (rheumatoid factor [RF]+ and/or anti-cyclic citrullinated peptide [anti-CCP]+) treated with abatacept…
Abstract Number: 0754 • ACR Convergence 2020
The Association Between Continuous Decreases in Serum RF Titers and Radiographic Remission of Joint Damage in RA Patients Treated with Biological or Targeted Synthetic DMARDs
Takayoshi Owada¹, Ayae Tanaka², Hirokuni Hirata¹, Masafumi Arima³, Yasutsugu Fukushima¹ and Kazuhiro Kurasawa³, ¹Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan, ²Dokkyo Medical University, Shimotsuga-Gun, Japan, ³Dokkyo Medical University, Mibu, Shimotsugagun, Tochigi, Japan
Background/Purpose: Rheumatoid factors (RFs) are RA-related autoantibodies like anti-cyclic citrullinated peptide antibodies, and are used for classifying and diagnosing RA. In addition, positivity and high…
Abstract Number: 0758 • ACR Convergence 2020
Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients
Dana Wiens¹, Irene Smolik¹, Xiaobo Meng¹, Vidyanand Anaparti¹, Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: The preclinical stage of Rheumatoid Arthritis (RA) is characterized by seropositivity for anti-citrullinated protein antibodies (ACPA). We (PubMed ID 30861615), and others, have shown that ACPA seropositivity…
Abstract Number: 0768 • ACR Convergence 2020
Dynamics of Follicular Helper T Cells Subsets in Rheumatoid Arthritis Patients Before and After Treatment
Paola Virginia Ferrero¹, Luisina Onofrio¹, Cristina del Valle Acosta¹, Estefania Raquel Zacca¹, Nicolas Eric Ponce², Eduardo Mussano¹, Ignacio Isaac Cadile¹, Laura Onetti¹, Marina Werner¹, Alicia Beatriz Costantino¹, Eva Virginia Acosta Rodriguez³ and Adriana Gruppi², ¹HOSPITAL NACIONAL DE CLINICAS, FACULTAD DE MEDICINA, UNIVERSIDAD NACIONAL DE CORDOBA, CORDOBA, Cordoba, Argentina, ²FACULTAD DE CIENCIAS QUIMICAS, UNIVERSIDAD NACIONAL DE CORDOBA. CENTRO DE INVESTIGACIONES EN BIOQUIMICA CLINICA E INMUNOLOGIA, CORDOBA, Cordoba, Argentina, ³FACULTAD DE CIENCIAS QUIMICAS, UNIVERSIDAD NACIONAL DE CORDOBA. CENTRO DE INVESTIGACIONES EN BIOQUIMICA CLINICA E INMUNOLOGIA, CORDOBA, Argentina
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by the production of autoantibodies like rheumatoid factor and anti- citrullinated protein. CD4+ follicular helper T…
Abstract Number: 0813 • ACR Convergence 2020
Treatment Outcomes in Patients with Seropositive versus Seronegative Rheumatoid Arthritis in Czech Registry ATTRA Treated with JAK Inhibitors
Karel Pavelka¹ and Zlatuše Křístková², ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
Background/Purpose: Seropositivity / seronegativity in RA may have influence on response to bDMARDs or tsDMARDs. There is incomplete knowledge of differences in efficacy of JAK…
Abstract Number: 1698 • ACR Convergence 2020
Polyarthritis Workup in Primary Care Setting : How Are We Doing?
Ruhani Desai¹, Cassandra Calabrese², Neel Patel³ and Jessica Donato⁴, ¹Cleveland Clinic Foundation, DeLand, FL, ²Cleveland Clinic, Cleveland, OH, ³Case Western Reserve University, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland
Background/Purpose: Joint pain is a common presenting complaint in Primary Care with around 54.4 million adults diagnosed with some form of arthritis per 2013 CDC survey. Polyarthritis…
Abstract Number: 1720 • ACR Convergence 2020
Factors Associated with an Increased Risk of Imminent Rheumatoid Arthritis in ACPA+ Individuals
Hyoun-Ah Kim¹, Ryan Peterson², Gary Firestein³, David Boyle⁴, Jane Buckner⁵, Sylvia Posso⁶, Eddie James⁵, William Robinson⁷, Jaron Arbet², LauraKay Moss⁸, Roger Gilmore⁸, Lindsay Hartje⁸, Saman Barzideh⁸, Jennifer Seifert⁹, Navin Rao¹⁰, Frédéric Baribaud¹¹, Sunil Nagpal¹², Alyssa Johnson¹³, V Michael Holers¹⁴ and Kevin D. Deane¹⁵, ¹University of Colorado Anschutz Medical Campus and Ajou University School of Medicine, Aurora, CO, ²Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, ³University of California, San Diego, La Jolla, CA, ⁴UC San Diego, San Diego, CA, ⁵Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Stanford University, Palo Alto, CA, ⁸University of Colorado Anschutz Medical Campus, Aurora, CO, ⁹Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Littleton, CO, ¹⁰Janssen R&D, Spring House, PA, ¹¹Janssen Research & Development, LLC, Spring House, PA, ¹²Janssen Reserach and Development, Spring House, PA, ¹³Janssen Research and Development, Spring House, PA, ¹⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ¹⁵2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado
Background/Purpose: Individuals at high-risk for future rheumatoid arthritis (RA) may be identified by screening for circulating RA-related autoantibodies including antibodies to citrullinated protein antigens (ACPA).…
Abstract Number: 1721 • ACR Convergence 2020
Increasing Autoantibody Positivity During Pre-RA Is Associated with the Imminent Development of Classifiable RA
Heinrich-Karl Greenblatt¹, Ted Mikuls², Jess Edison³, Marie Feser⁴, Mark Parish⁵, LauraKay Moss⁵, Elizabeth Mewshaw⁶ and Kevin D. Deane⁷, ¹University of Colorado School of Medicine, Aurora, CO, ²University of Nebraska Medical Center, Omaha, NE, ³Walter Reed National Military Medical Center, Bethesda, ⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Walter Reed National Military Medical Center, Bethesda, MD, ⁷2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado
Background/Purpose: Autoantibodies including rheumatoid factor (RF) and antibodies to citrullinated protein antigens (ACPA) may be elevated during a period that can be termed ‘Pre-RA’. In…
Abstract Number: 1753 • ACR Convergence 2020
Substantial Work Limitations in Patients with Rheumatoid Arthritis Despite Optimal Treat-to-Target (T2T) Drug Therapy Intervention
Sara Eileen Meyer¹, Julianna Rachel Hoeper², Kirsten Hoeper¹, Torsten Witte³ and Dirk Meyer-Olson⁴, ¹Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., Hanover, Germany, ²Center for Health Economics Research Hannover, Leibniz Universität Hannover, Hannover, Hanover, Germany, ³Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., Hannover, Germany, ⁴Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., m&i Fachklinik Bad Pyrmont und Medizinisches Forschungszentrum Weserbergland, Hanover, Germany
Background/Purpose: Rheumatoid arthritis (RA) is associated with restrictions on occupational participation caused by periods of sick leave (absenteeism), reduced productivity at work due to disease…

« Previous Page
1
…
4
5
6
7
8
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].